Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘No Decision’ On Sandoz As Novartis Continues To Explore Options

Update To Strategic Review Likely By The End Of The Year

Executive Summary

Novartis said it had so far made “no decision” as it continues to consider numerous options for Sandoz, from retaining the business to separation, in order to maximize value for shareholders and capitalize upon the growing autonomy of its generics business.

You may also be interested in...



Bourdage Becomes COO As Sandoz Shuffles Management

A management reshuffle at Sandoz has seen head of biopharmaceuticals Pierre Bourdage take on the role of chief operating officer among a number of changes, as parent company Novartis continues its strategic review of the generics and biosimilars unit.

Sandoz Says All Options Still Open After Spinoff Rumors

Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.

Generics Bulletin Editor’s Picks For Q1 2022

Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel